Neurocrine Biosciences Inc

Neurocrine Biosciences insider buy signals confidence; CEO’s 12,830 option exercise reflects bullish outlook amid solid clinical data and low risk‑profile pipeline.

Insider buying at Neurocrine signals confidence in its neuro‑psychiatric pipeline and market‑access strategy, suggesting undervalued upside for investors.